Gene therapy targeting BCL11A to induce fetal hemoglobin and reduce sickle hemoglobin in patients with Sickle Cell Disease
$1,200,379OT2FY2020HLNIH
Boston Children'S Hospital, Boston MA
Investigators
Linked publications, trials & patents
Abstract
No abstract provided
View original record on NIH RePORTER →